Drug Maker Staging a Comeback After Yesterday’s Debacle

Health and Healthcare

Published: December 14, 2012 11:54 am

Last Updated: April 27, 2020 8:32 pm

Drug developer Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) watched its shares plummet 35% yesterday following a report that rheumatoid arthritis treatment it was developing with AstraZeneca plc (NYSE: AZN) did not show the expected benefits in a mid-stage drug trial. Compared with a competitive drug, Humira, from Abbott Laboratories (NYSE: ABT), fostamatinib, the drug licensed by Rigel to AstraZeneca, did not perform as well.

This was doubly bad news for Rigel, for which fostamatinib is its only drug with near-term economic potential. The company has other drugs in its pipeline, but only one is set to begin Phase II trials next year and others are even further in the future.

AstraZeneca has said it will continue with larger study on fostamatinib’s benefits, and that is probably what’s bringing Rigel a little relief today. AstraZeneca licensed the drug from Rigel for $100 million cash and a potential $345 million more if certain benchmarks are reached. Rigel could also receive up to $800 million in royalty payments once the drug hits the market.

Shares of Rigel are up 15.5% today after yesterday’s beating. Just before noon shares are trading at $6.36 in a 52-week range of $5.37 to $11.44.

Paul Ausick

Cash Back Credit Cards Have Never Been This Good

Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.